Inflection Pharma Consulting ApS: Financial statements 2019
CVR: 39685507
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Inflection Pharma Consulting ApS (CVR 39685507) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 36,496 and a net result of DKK 27,608. Equity in the 2019 report amounted to DKK 81,851. The solvency ratio was 77.5%.
- Gross Profit
- DKK 36,496
- Profit/Loss
- DKK 27,608
- Equity
- DKK 81,851
- Total Assets
- DKK 105,642
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Inflection Pharma Consulting ApS has published its interim report for the period June 27, 2018 – December 31, 2018.
As of March 27, 2019, Mads Kristian Dalsgaard is registered as director of Inflection Pharma Consulting ApS.
As of March 27, 2019, Henrik Bernt Sanders has stepped down as liquidator of Inflection Pharma Consulting ApS.
On March 27, 2019, Inflection Pharma Consulting ApS exited liquidation.
As of February 20, 2019, Henrik Bernt Sanders is registered as liquidator of Inflection Pharma Consulting ApS.
On February 20, 2019, Inflection Pharma Consulting ApS entered liquidation.
As of January 17, 2019, Mads Kristian Dalsgaard has stepped down as director of Inflection Pharma Consulting ApS.
About Inflection Pharma Consulting ApS
Inflection Pharma Consulting ApS was a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company has been dissolved on 1 November 2022. The company was registered under the industry Anden teknisk rådgivning. In 2021, the company reported a gross profit of DKK -1,832 and a net result of DKK -11,890 compared with DKK 36,237 the year before. Equity in the 2021 report amounted to DKK 93,827.